J-147 Capsules10mgpercapsule/singlebottle-packof60
- Batch
- J147-CA-26H-10
- Tested by
- Janoshik
- Tested on
- 2026-09-02
- Added
- 2026-10-03
J-147 Capsules
J-147 Capsules USA — Capsules
Curcumin-Derived Neuroprotective Hydrazide
Also known as J147
J-147 is a synthetic hydrazide derived structurally from curcumin, developed for laboratory research. It is supplied in capsule form for controlled experimental use and is not a peptide.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
J-147 is a synthetic hydrazide derived structurally from curcumin, developed for laboratory research. It is supplied in capsule form for controlled experimental use and is not a peptide.
In scientific literature, J-147 appears in preclinical models examining mitochondrial function, oxytosis/ferroptosis cell death pathways, and markers of brain aging. Published work is largely rodent and cell-based, with no human clinical record established in the available references.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
J-147 is a trifluoromethyl phenyl hydrazide evaluated in research on mitochondrial and oxidative stress pathways. Reported work identifies the mitochondrial ATP synthase alpha subunit as a binding target, with downstream effects described on calcium handling, CAMKK2/AMPK signaling, and acetyl-CoA levels in experimental systems. Separate lines of investigation have placed the compound within screening frameworks for inhibitors of the oxytosis/ferroptosis cell death pathway, a non-apoptotic mode of death linked in the literature to glutathione depletion and lipid peroxidation.
Research endpoints evaluated in the published record include microglial polarization and neuroinflammatory markers in rodent models, cognitive and anxiety-related behavioral measures following surgery in Zucker rats, transcriptional and metabolic markers of brain aging in mice, and comparative geroprotective profiling against other candidate compounds. Metabolic fate and in vitro toxicology and genotoxicity characterization have also been reported.
J-147 originated in medicinal chemistry work on curcumin-derived scaffolds screened in cell-based assays relevant to neurodegeneration rather than against a predefined molecular target. Early reports described its metabolism as a hydrazide lead compound and characterized its in vitro safety and genotoxicity profile within preclinical assessment panels.
Subsequent research identified mitochondrial ATP synthase as a molecular interaction partner, which connected the compound to the broader mitochondrial hypothesis of age-associated neurological disease. Later publications extended the record into oxytosis/ferroptosis screening, brain aging and acetyl-CoA metabolism, microglial signaling, and behavioral models, and the compound has been reviewed as a research candidate in nervous system disease. The literature remains preclinical.
Laboratory investigations into J-147 span mitochondrial bioenergetics, oxidative cell death pathway screening, and neuroinflammation models. Research frameworks have examined ATP synthase interaction, CAMKK2/AMPK signaling and microglial polarization, acetyl-CoA and brain aging markers, oxytosis/ferroptosis inhibition in cultured neuronal cells, and behavioral endpoints in rodents, alongside metabolism and in vitro toxicology characterization.
3 of the 5 areas below are addressed directly by a paper cited on this page.
Mitochondrial ATP synthase interaction studies
No paper cited on this page reports on mitochondrial, synthase or interaction. This heading marks where J-147 Capsules is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Oxytosis/ferroptosis pathway screening
Addressed on this page by Maher 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Maher, P. et al. (2020) — Using the Oxytosis/Ferroptosis Pathway to Understand and Treat Age-Associated Neurodegenerative Diseases
Neuroinflammation and microglial polarization models
Addressed on this page by He 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- He, L. et al. (2025) — J147 modulates microglial polarization via CAMKK2/AMPK signaling to ameliorate neuroinflammation
Brain aging and acetyl-CoA metabolism research
Addressed on this page by Currais 2019, Chiruta 2013. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Currais, A. et al. (2019) — Elevating acetyl-CoA levels reduces aspects of brain aging
- Chiruta, C. et al. (2013) — Metabolism of a potent neuroprotective hydrazide
Rodent behavioral and cognition models
No paper cited on this page reports on rodent, behavioral or cognition. This heading marks where J-147 Capsules is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 6 primary papers published between 2013 and 2025 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
J-147 Capsules is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for J-147 Capsules, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
J-147 Capsules is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under mitochondrial ATP synthase interaction studies, oxytosis/ferroptosis pathway screening and neuroinflammation and microglial polarization models.
The 6 papers cited on this page, published between 2013 and 2025 (1 review) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for J-147 Capsules is per lot, not per product. The current 10mgpercapsule/singlebottle-packof60 lot J147-CA-26H-10 returned 13.69 mg measured, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
The lot code printed on the bottle matches the code on the certificate for J-147 Capsules. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy J-147 Capsules in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Storage
- Cool, dry, away from direct light
- Humidity
- Keep sealed; capsule shells are hygroscopic
- Reconstitution
- Not applicable — supplied pre-measured
- Format
- Oral capsule
J-147 Capsules is supplied in capsule form, which removes the reconstitution step entirely: there is no vehicle to add, no reconstitution volume to record and no post-reconstitution stability window to track. What that leaves a laboratory to control is storage — capsule shells draw moisture from the air, so the container should be kept sealed and dry rather than decanted into an open vessel.
Because the material is already at its labelled quantity per capsule, batch verification carries more weight in this format than it does for powder: there is no point at which the researcher independently confirms mass by weighing. The measured content published for each lot is the figure that answers that question.
- 1 × sealed capsule bottle (10mg per capsule / Single Bottle - Pack of 60), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Laboratory consumables of any kind
- Dosing, administration or protocol guidance of any kind
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each capsule contains the labeled quantity of J-147. Independent third-party analysis verifies purity, identity, and net content per batch.
The container holds only the capsules. Any laboratory materials required for sample preparation or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Current evidence for J147 as a potential therapeutic agent in nervous system disease: a narrative review
PubMedJ147 modulates microglial polarization via CAMKK2/AMPK signaling to ameliorate neuroinflammation
PubMedUsing the Oxytosis/Ferroptosis Pathway to Understand and Treat Age-Associated Neurodegenerative Diseases
PubMedRelated
You May Also Like
Fisetin-Derived Research Compound CMS-121 is a synthetic small molecule derived from the plant flavonoid fisetin, produced for laboratory research use only. It is supplied in capsule form for controlled experimental work and is not intended for any other application.
$29.99
Methylated Beta-Carboline Alkaloid 9-Me-BC (9-methyl-beta-carboline) is a small methylated beta-carboline alkaloid studied in neurochemical research models. It is supplied in capsule form strictly for laboratory research use.
$64.99
Uncharacterised Research Compound Compound-7P is supplied as capsules for laboratory research use. The designation "Compound-7P" is a non-systematic label and does not correspond to a single identified chemical entity in the published chemical or pharmacological literature. No PubChem record matches the name, and no molecular formula, sequence or structural profile was supplied with it.
$49.99
Redox-Active Flavin Analogue 5-Deazaflavin is a synthetic analogue of the flavin ring system in which the nitrogen at position 5 of the isoalloxazine core is replaced by carbon. The parent heterocycle (C11H7N3O2, MW 213.19) and its substituted derivatives are produced for laboratory research and are handled within controlled experimental environments.
$59.99